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Abstract
Background: Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma in adolescents and young adults. The hallmark
of this disease is a EWS-WT1 translocation resulting from apposition of the Ewing’s sarcoma (EWS) gene with the Wilms’
tumor (WT1) gene. We performed morphoproteomic profiling of DSRCT (EWS-WT1), Ewing’s sarcoma (EWS-FLI1) and Wilms’
tumor (WT1) to better understand the signaling pathways for selecting future targeted therapies.
Methodology: This pilot study assessed patients with DSRCT, Wilms’ tumor and Ewing’s sarcoma. Morphoproteomics and
immunohistochemical probes were applied to detect: p-mTOR (Ser2448); p-Akt (Ser473); p-ERK1/2 (Thr202/Tyr204); p-STAT3
(Tyr 705); and cell cycle-related analytes along with their negative controls.
Principal Findings: In DSRCT the PI3K/Akt/mTOR pathway is constitutively activated by p-Akt (Ser 473) expression in the
nuclear compartment of the tumor cells and p-mTOR phosphorylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as
the dominant form. Ewing’s sarcoma had upregulated p-Akt and p-mTOR, predominantly mTORC2. In Wilm’s tumor, the
mTOR pathway is also activated with most tumor cells moderately expressing p-mTOR (Ser 2448) in plasmalemmal and
cytoplasmic compartments. This coincides with the constitutive activation of one of the downstream effectors of the
mTORC1 signaling pathway, namely p-p70S6K (Thr 389). There was constitutive activation of the Ras/Raf/ERK pathway p-
ERK 1/2 (Thr202/Tyr204) expression in the Wilms tumor and metastatic Ewing’s sarcoma, but not in the DSRCT.
Conclusion: Morphoproteomic tumor analyses revealed constitutive activation of the mTOR pathway as evidenced by: (a)
expression of phosphorylated (p)-mTOR, p-p70S6K; (b) mTORC 2 in EWS and DSRCT; (c) ERK signaling was seen in the
advanced setting indicating these as resistance pathways to IGF1R related therapies. This is the first morphoproteomic
study of such pathways in these rare malignancies and may have potential therapeutic implications. Further study using
morphoproteomic assessments of these tumors are warranted.
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Introduction
Desmoplastic small round cell tumor (DSRCT) is a rare
sarcoma that presents as diffuse peritoneal sarcomatosis in
children, adolescents and young adults, predominantly males
[1,2]. Because of its rarity, it is often misclassified as being other
small round blue cell tumors. Ewing’s sarcoma (ES) is the second
most common bone tumor in children, adolescents and young
adults. Traditionally, DSRCT patients have been treated similarly
to ES patients using an algorithm that incorporates surgery,
radiation therapy, and multidrug chemotherapy [3]. The progno-
sis of relapsed DSRCT is poor and achievement of durable
remission remains elusive [2].
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Wilms’ tumor (WT), or nephroblastoma, is a neoplasm of the
kidneys that typically occurs in children [4]. The prognosis is
dependent on histology and staging [5]. The use of chemotherapy
combined with surgery and radiotherapy has greatly improved the
outcome of WT patients, with more than 90% being cured [6].
However, the treatment of advanced and high-risk WT remains a
challenge.
DSRCT, WT and ES share a chimeric relationship with one
another. DSRCT is caused by the translocation of the EWSR1
gene from chromosome 22 to chromosome 11, resulting in a
fusion product EWSR1/WT1 [7]. ES is caused by the transloca-
tion of the EWSR1 gene from chromosome 22 to chromosome 11
in most cases (EWSR1-FLI1) and chromosomes 21 [8] and 7 in
rare cases (EWSR1-ERG and EWSR1-ETV1) [9,10]. Mutation of
the WT1 gene on chromosome 11 is observed in 20% of WT cases
[11]. A CTNNB1 mutation is also seen in 14% of WT cases and
the WT1 and CTNNB1 mutations are highly associated [12].
Because DSRCT, ES and WT seem to be genetically close
cousins, presenting in young patients and responding to similar
cytotoxic active agents, comparing the signaling pathways is a
rational approach toward delineating the biology of these rare
tumors.
Here, we report our experience with two index cases of DSRCT
and WT with a detailed clinical history and assessment of
morphoproteomic signaling for profiling and comparing two
previously reported ES cases to elucidate current and future
therapeutic options [13]. We show mTOR pathway signaling in
these interesting tumors. Moreover, ERK pathway signaling seen
in the advanced setting suggests that it is a resistance pathway.
Methods
Patient Selection
We reviewed the medical records of a patient with DSRCT and
a patient with WT. Both patients were seen in the Departments of
Investigational Cancer Therapeutics and Pediatrics at The
University of Texas MD Anderson Cancer Center (MD
Anderson). This study was performed in accordance with the
guidelines of the MD Anderson Institutional Review Board (IRB),
as previously described [13].Because this was a retrospective chart
review IRB has waived the consent requirements.
Immunohistochemical and Morphoproteomic Analyses
Immunohistochemical and morphoproteomic analyses of
tumor samples collected from each patient were performed, as
previously described [13]. Briefly, this pilot study assessed two
patients, one with DSRCT (Pt #1), and the other with Wilms’
tumor (#2) and compared them with our previously reported
ES patients. Morphoproteomics and immunohistochemical
probes [13] were used to detect p-mTOR (Ser2448), p-Akt
(Ser473), p-ERK1/2 (Thr202/Tyr204), p-STAT3 (Tyr 705),
VEGF-A expression, cell cycle related analytes including Ki67,
cyclin-D1 and Skp 2 along with negative and positive controls.
All analyses were performed at The University of Texas at
Houston certified under the Clinical Laboratory Improvement
Amendments of 1988 (‘‘CLIA’’) as qualified to perform high-
complexity clinical testing.
Results
The clinical history of the four patients in this pilot studies and
their responses to chemotherapy and targeted therapy are
reviewed below.
Patient 1. A sixteen-year-old white male presented with
massive abdominal distension and dyspnea that worsened with
exertion. A PET/CT scan revealed extensive abdominal disease,
including a dominant 28 cm mass, all of which were FDG avid. A
biopsy showed a small round blue cell tumor consistent with the
diagnosis of DSRCT. The patient was initially treated with
chemotherapy, similar to the treatment of ES, consisting of
vincristine, adriamycin, and cyclophosphamide, alternating with
etoposide and ifosfamide for a total for 3 cycles. He then received
sunitinib(oral small molecule, multi-targeted anti-angiogenic
receptor tyrosine kinase inhibitor) for 6 weeks and was referred
to MD Anderson for further management. The patient received 5
cycles of systemic therapy before harvesting his stem cells. He then
underwent cytoreductive surgery followed by hyperthermic
intraperitoneal cisplatin. His next treatment regimen was temo-
zolomide and irinotecan before whole abdominal radiation
therapy, followed by switching to weekly vinorelbine with daily
oral cyclophosphamide. Following relapse, the patient was started
on pazopanib, a multi-kinase inhibitor anti-angiogenic agent, and
the mTOR inhibitor rapamycin before switching again to
vincristine, adriamycin, cyclophosphamide alternating with eto-
poside and ifosfamide for a total for 6 cycles. He was then given
temozolomide concomitant with radiation before eventually
receiving PEG-interferon at the time of last follow up.
Patient 2. A sixteen-year-old white female was initially
diagnosed with Wilms’ tumor by radical nephrectomy. The
patient received actinomycin-D and vincristine and developed
recurrence in the lungs. Biopsy of the lung nodule confirmed
Wilms’ tumor. She received 1 cycle of vincristine plus doxorubicin
before switching to cyclophosphamide plus etoposide. She then
received ‘‘ICE-T’’ (ifosfamide, etoposide, carboplatin plus topote-
can) before undergoing a double autologous stem cell rescue with
cyclophosphamide, carboplatin, etoposide and melphalan. This
was followed by radiation to the lungs. After developing
progression in lung metastasis, she was enrolled on a phase I
study with sorafenib(multi-kinase anti-angiogenic inhibitor target-
ing several tyrosine protein kinases including the Raf kinases ),
resulting in a 25% decrease in the size of her lung metastases
followed by stable disease for 8 months. After progression, she was
enrolled on a phase I study of temsirolimus, a mammalian target of
rapamycin (mTOR) inhibitor, in combination with the insulin-like
growth factor (IGF1R) inhibitor IMC-A12. Unfortunately she
progressed on this treatment. She was then treated with rapamycin
and sunitinib, with discontinuation of rapamycin following grade 4
thrombocytopenia. She then progressed on liposomal doxorubi-
cin+bevacizumab (avastin) and then liposomal doxorubicin+bor-
tezomib (velcade, proteasome inhibitor). She was then referred to
the Phase I Clinic at MDAnderson, enrolled on a checkpoint
kinase (CHK) inhibitor study, and then, unfortunately, she
progressed on therapy and was taken off the study.
Patients 3 & 4 (ES). Briefly, patients #3 and #4 were a 24-
year-old white female and 21-year-old white male diagnosed with
ES. Both patients progressed on several lines of standard
chemotherapy for ES and were referred for enrollment on Phase
I clinical trials. Interestingly, both patients had a significant
response to single agent Insulin like growth factor 1 receptor
(IGF1R) antibodies. Following progression on single-agent IGF1R
antibody treatment, both patients were enrolled on a combined
IGF1R+mTOR inhibitor therapy. Patient #3 continues on
therapy for more than 6 years on IGF1R inhibitor based therapy,
whereas patient #4 progressed. The results with detailed
correlative morphoproteomics have been published [13].
DSRCT, Ewing’s Sarcoma and Wilms’ Tumor
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Figure 1. Morphoproteomics and Immunohistochemistry Patients #1, 2. In patient #1 (DSRCT) the PI3K/Akt/mammalian target of
rapamycin (mTOR) pathway is constitutively activated by p-Akt (Ser 473) expression in the nuclear compartment of the tumor cells and p-mTOR
phosphorylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as the dominant form. In patient #2 (Wilm’s tumor), the mTOR pathway is also
activated with most tumor cells moderately expressing p-mTOR (Ser 2448) in plasmalemmal and cytoplasmic compartments. This coincides with the
constitutive activation of one of the downstream effectors of the mTORC1 signaling pathway, namely p-p70S6K (Thr 389). There is constitutive
activation of the Ras/Raf kinase/extracellular signal-regulated kinase (ERK) pathway p-ERK 1/2 (Thr202/Tyr204) expression in the Wilms tumor.
doi:10.1371/journal.pone.0068985.g001
DSRCT, Ewing’s Sarcoma and Wilms’ Tumor
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Morphoproteomics/Immunohistohemistry and
Correlative Studies
The morphoproteomics results are summarized in Table 1 and
Figure 1.
Patient 1 (DSRCT). Sections of tumor tissue from cytor-
eductive surgery were available. There is minimal constitutive
activation of the Ras/Raf kinase/ERK pathway as evidenced by
the expression of phosphorylated (p-) extracellular signal-regulated
kinase (ERK) 1/2 (Thr 202/Tyr204) with nuclear translocation in
only a rare tumor cell. It may be relevant that vincristine can cause
inactivation of ERK [14]. In contrast, the PI3K/Akt/mTOR
pathway is constitutively activated by the expression of p-Akt (Ser
473), almost exclusively in the nuclear compartment of the tumor
cells and of p-mTOR phosphorylated on Ser 2448, also with
variable mild to moderate nuclear expression. This pattern of
expression with nuclear subcellular compartmentalization suggests
that mTORC2 (rictor+mTOR) is the dominant form
[15,16,17,18]. Most of the tumor cells were also immunopositive
for nestin, a neural precursor/differentiation marker. Nestin has
been identified and reported previously in DSRCT [19]. Notably,
a minor but significant portion of the tumor nuclei express p-signal
transducer and activator of the transcription (STAT) 3 (Tyr 705) in
their nuclei in some regions (Figure 1).
Patient 2 (WT). Lung biopsy was performed after the patient
progressed on doxil+bortezomib(velcade). The mTOR pathway is
activated, with the vast majority of tumor cells showing moderate
expression of p-mTOR (Ser 2448) on the plasmalemmal and
cytoplasmic compartments. This coincides with constitutive
activation of a downstream effector of the mTORC1 signaling
pathway, p-p70S6K (Thr 389) in ,90 to 95% of tumoral nuclei
[20]. The expression of both nuclear and cytoplasmic p-Akt (Ser
473) raises the possibility of mTORC2 pathway signaling as well.
There is constitutive activation of the ras/Raf kinase/ERK
pathway in the form of p-ERK K (Thr202/Tyr204) expression,
showing nuclear translocation [21] in ,90% of the tumor cells. In
addition, the STAT pathway appears activated in approximately
20% of the tumor with nuclear translocation of p-STAT3 (Tyr
705). Nestin is negative or weakly expressed.
Patients 3 and 4. Briefly, in the two patients with ES, p-Akt
and p-mTOR, predominantly mTORC2, were upregulated in
initial biopsies before the IGF1R inhibitor therapy. In patient #4,
who responded to the combined IGF1R+mTOR targeted therapy
and then relapsed, the resistant tissue showed activation of the
ERK pathway as well. This was speculated from the evidence of
constitutive activation of the p-ERK 1/2 (Thr202/Tyr204)
expression, showing nuclear translocation (Table 1).
Discussion
We have shown the morphoproteomic signaling pathways of a
DSRCT patient and a WT patient and compared them to two
previously reported patients with ES. [13] In this small observa-
tional study we demonstrated the mTOR signaling pathway
involvement among these three interesting tumors(Figure 2). In the
patient with DSRCT the PI3K/Akt/mTOR pathway is constitu-
tively activated by virtue of the expression of p-Akt (Ser 473) in the
nuclear compartment of the tumor cells, and p-mTOR phosphor-
ylated on Ser 2448, suggesting mTORC2 (rictor+mTOR) as the
dominant form. In the patients with ES, there was upregulation of
p-Akt and p-mTOR, predominantly mTORC2. In the patient
with WT, the mTOR pathway is also activated with most tumor
cells showing moderate expression of p-mTOR (Ser 2448) in the
plasmalemmal and cytoplasmic compartments. This coincides
with the constitutive activation of one of the downstream effectors
of the mTORC1 signaling pathway, p-p70S6K (Thr 389). There
was constitutive activation of the ERK, with p-ERK 1/2 (Thr202/
Tyr204) expression in the WT and ES patients in the advanced
setting, but not in the DSRCT patient.
In patient #1 (DSRCT), the deactivation of Ras/Raf/ERK
pathway is consistent with a previous finding that vincristine can
inactivate ERK [14]. Meanwhile, it could be speculated that
activation of p-Akt caused activation of the PI3K/Akt/mTOR
pathway, which provided a bypass for the Ras/Raf/ERK pathway
and resulted in subsequent tumor growth. The expression pattern
of p-mTOR suggested that mTORC2 is the dominant form in
DSRCT. Of interest, mTORC2 is also the dominant form in ES,
as previously reported. The next rational treatment regimen for
patient #1 would be rapamycin, which after long exposure,
suppresses the formation of mTORC2, thus inhibiting the
mTORC2 pathway [17]. Given this molecular background, the
patient was treated with pazopanib and rapamycin combination
therapy, but was taken off therapy after 10 days due to a
pulmonary embolism. Because mTORC2 phosphorylates S473 of
AKT, an AKT inhibitor might be of benefit in the next line of
treatment. In addition, IGF1R-related therapy is also a candidate
as IGF1R is one of the key regulators of the mTORC2 pathway.
Of interest morphoproteomic analysis of insulin-like growth
factor(IGF) pathway reveals constitutive activation of IGF-
1receptor as evidenced by the expression of phosphorylated (p)-
IGF-1R (Tyr1165/1166) on the plasmalemmal aspect and in
Table 1. Morphoproteomic profiling of patients with DSRCT, Wilms’ tumor and Ewing’s sarcoma.
Patient # and
Diagnosis* P #1 DSRCT
Pt #2 Wilms’
Tumor Pt #3 Ewing’s sarcoma Pt #4 Ewing’s sarcoma
Biopsy Timeline Before IGF1R After IGF1R Before IGF1R After IGF1R+mTOR
p-mTOR{ 1–2+,N, stromal
cells 2–3+
2+, P-C, .50% 621+/621+ 1–3+/1+ 0–2+/6 1–3+/6
p-Akt{ 623+, N, 1+/1+, N/C, ,90% 026/621+ 1–3+/1–2+ 0–2+/6 623+/6
p-STAT3{ 0–3+, N 2–3+, N, ,20% 0–3+ 0–3+
Nestin{ 0–3+, C/P, majority 0 0 0 0–1+ 0–3+
p-ERK1/2{, ` 026, N, 3+/2+, N/C, ,90% N/A N/A 0–3+, N/C 1–3+/6
*Scoring intensity graded on a scale of 0 (no signal) to 3+ (high intensity). N-Nuclear,C-Cytoplasmic,P-Plasmalemmal.
{Plasmalemmal;
`Thr 202/Tyr 204 [Nuclear].
doi:10.1371/journal.pone.0068985.t001
DSRCT, Ewing’s Sarcoma and Wilms’ Tumor
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cytoplasmic compartments of the tumor cells in DSCRT
(Patient#1) (Figure 3).
In patient #2 (WT), the constitutive activation of mTORC1 is
evidenced by the activation of p-p70S6K (Thr 389). In addition,
the expression of both nuclear and cytoplastmic p-Akt (S473) also
suggests mTORC2 pathway signaling. The activation of both
mTORC1 and mTORC2 could be consistent with IGF1R
signaling reported in WT [22]. However, in spite of activated p-
Akt and the mTOR pathway, patient #2 did not respond to
IGF1R+mTOR inhibitor therapy.
To explicate mechanisms of tumor resistance, we compared
patient #2 with two EWS patients (patients 3&4) who initially
responded to IGF1R+mTOR inhibitor therapy. In fact, patient
#3 remains on therapy, whereas patient #4 developed resistance
after four months [13]. Comparing the three patients suggests that
the activation of Ras/Raf/ERK pathway may be a key player in
diverse responses. The Ras/Raf/ERK pathway provides a bypass
for the mTOR pathway and, therefore, may result in tumor
resistance. This is consistent with the observation that activation of
the Ras/Raf/ERK pathway was observed in the tumor both of
patient #2 and the tumor resistance of patient #4. We then
compared the p-ERK1/2 level between those two patients and
found that the level of p-ERK level expression in patient #2 was
significantly higher than in patient #4, while the levels of p-Akt
and p-mTOR were comparable between both patients. These
results suggest that the Ras/Raf/ERK pathway may be the
dominant pathway in patient #29s tumor. In contrast, patient
#49s tumor was initially regulated primarily by the Akt/mTOR
pathway, which explains his initial response to the therapy.
However, the Ras/Raf/ERK pathway then gained dominance,
driving tumor resistance. Therefore, the next logicial line of
treatment for patient #2 would likely be a ERK/MEK inhibitor
combined with IGF1R+mTOR inhibitors.
Morphoproteomic analyses revealed a similarity among
DSRCT, ES and WT in the constitutive activation of the mTOR
pathway, evidenced by the expression of p-mTOR and p-p70S6K.
We also found that mTORC2 is the dominant form in both ES
and DSRCT, whereas mTORC1 is activated in WT. Our results
also suggest a mechanism that may be used to predict response to
IGF1R/mTOR inhibitor therapy, which is to compare Akt/
mTOR pathway and Ras/Raf/ERK pathway activation. If the
IGF1R/mTOR pathway is the dominant pathway, the patient
may respond to IGF1R-related therapy. Otherwise the patient’s
tumor might be resistant to IGF1R inhibitor therapy. Although we
Figure 2. Simplified mTORC 1 and 2 pathway and the relationship with WT1, EWS-FLI-1 and EWS-WT1. Morphoproteomic analyses
shows a similarity among DSRCT, ES and WT in the constitutive activation of the mTOR pathway, evidenced by the expression of p-mTOR and p-
p70S6K. We also found that mTORC2 is the dominant form in both ES and DSRCT, whereas mTORC1 is activated in WT. Our results also suggest a
mechanism that may be used to predict response to IGF1R/mTOR inhibitor therapy, which is to compare Akt/mTOR pathway and Ras/Raf/ERK
pathway activation. If the IGF1R/mTOR pathway is the dominant pathway, the patient may respond to IGF1R-related therapy.
doi:10.1371/journal.pone.0068985.g002
DSRCT, Ewing’s Sarcoma and Wilms’ Tumor
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realize these are very preliminary observations on a few patients
morphoproteomic analysis provided insights that need to be
confirmed in larger samples to avoid sampling error as well as
increased numbers of these 3 tumors. If mTOR is confirmed, this
may have potential implications for future molecularly targeted
therapies to inhibit metastases of these small round blue-cell
malignancies. One limitation of the study is that the examined
tissues are post-chemotherapy resected tumors and that activation
of mTOR pathway could be due to chemotherapy treatment
rather than by the tumor-specific genetic or epigenetic alterations.
In summary, morphoproteomic analyses of the patients’ tumors
in this pilot study revealed constitutive activation of the mTOR
pathway as evidenced by: (a) expression of phosphorylated (p)-
mTOR and p-p70S6K; (b) mTORC 2 in ES and DSRCT; (c)
ERK signaling was seen in the advanced setting, pointing to these
as resistance pathways to IGF1R+mTOR-based therapies. This is
the first morphoproteomic study demonstrating mTOR signaling
pathway in these rare malignancies and may have potential
therapeutic implications. Further morphoproteomic assessments of
these tumors are warranted.
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